CN105106303A - Medical application of selfheal aqueous extract - Google Patents
Medical application of selfheal aqueous extract Download PDFInfo
- Publication number
- CN105106303A CN105106303A CN201510604313.2A CN201510604313A CN105106303A CN 105106303 A CN105106303 A CN 105106303A CN 201510604313 A CN201510604313 A CN 201510604313A CN 105106303 A CN105106303 A CN 105106303A
- Authority
- CN
- China
- Prior art keywords
- spica prunellae
- water extract
- prunellae water
- diabetic retinopathy
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of medicine, in particular to medical application of a selfheal aqueous extract. The medical application comprises 0.1 to 20 wt% of rosmarinic acid, and can be used for treating diabetic retinopathy.
Description
Technical field
The present invention relates to Medicines and Health Product field, particularly relate to a kind of medical usage of Chinese medicinal plant extract.
Background technology
Diabetic retinopathy (Diabeticretinopathy, DR) is one of most important performance in diabetic microangiopathy, and being a kind of retinopathy having specificity and change, is one of severe complication of diabetes.Clinically according to whether occurring that retinal neovascularization is mark, retinal neovascularazation will do not had, but the diabetic retinopathy that blood-retina barrier (BRB) seepage and retina inflammatory damage occur is called nonproliferative diabetic retinopathy (nonproliferativediabeticretinopathy, NPDR) (or claiming simple type or background type), and by there being the diabetic retinopathy of retinal neovascularazation to be called, proliferating diabetic retinopathy becomes (proliferativediabeticretinopathy, PDR).The former main manifestations is that retina is dispersed in microangioma, some lamellar hemorrhage, hard exudate, macular edema etc.; Latter shows as retina or looks nipple new vessels and formed, and to vitreous body growth, easily vitreous hemorrhage and tractive detachment of retina occurs.
Spica Prunellae (PrunellavulgarisL), another name wheat head Spica Prunellae, iron wire Spica Prunellae (Yunnan book series), Mai Xia is withered, the iron wire summer is withered (the southern regions of the Yunnan Province book on Chinese herbal medicine), sunset sentence etc., be Labiatae Herba lamii barbati subfamily herbaceos perennial.Dry fruit ear is used as medicine, and strong adaptability, all parts of the country are all produced.Its property of medicine is pungent, bitter, cold, returns liver, gallbladder meridian, has clearing away heat-fire, improving eyesight, effect of mass dissipating and swelling eliminating.Be used for treating conjunctival congestion and swelling pain, dizzy, order pearl nyctalgia of having a headache, scrofula, goiter, acute mastitis swells and ache.Rosmarinic acid (the C contained in Spica Prunellae extract
18h
16o
8) be that in pharmacopeia, Spica Prunellae is differentiated and the index components of assay.
Summary of the invention
Object of the present invention aims to provide a kind of novelty teabag of Spica Prunellae water extract.
Specifically, a first aspect of the present invention there is provided the application of a kind of Spica Prunellae water extract in the medicine preparing prevention or treatment diabetic retinopathy or food, and described Spica Prunellae water extract is containing 0.1 ~ 20wt% rosmarinic acid.
In a preference, described Spica Prunellae water extract is containing 1.98wt% rosmarinic acid
In another preference, described diabetic retinopathy is non-proliferative diabetic retinopathy.
The details of various aspects of the present invention is able to detailed description by chapters and sections subsequently.By hereafter and the description of claim, feature of the present invention, object and advantage will be more obvious.
Accompanying drawing explanation
Fig. 1 Spica Prunellae water extract (PV) is on impact (A) body weight of diabetic mice body weight and blood glucose; (B) blood glucose; (
n=16)
###p<0.001vs. blank;
Fig. 2 Spica Prunellae water extract (PV) on the impact of diabetic mice BRB seepage (
n=6)
###p<0.001vs. blank; * * P<0.001vs. diabetic groups;
Fig. 3 Spica Prunellae water extract (PV) reduce raise in diabetic mice serum IL-1 β, TNF-alpha content (
n=10)
#p<0.05vs. blank; * P<0.05, * * P<0.01, * * * P<0.001vs. diabetic groups;
Fig. 4 Spica Prunellae water extract (PV) in diabetic mice retina Iba-1 express impact (
n=8)
###p<0.001vs. blank; * * P<0.001vs. diabetic groups;
Fig. 5 Spica Prunellae water extract (PV) on the impact of NF-κ Bp65 subunit phosphorylation and nuclear translocation in diabetic mice retina (
n=8)
###p<0.001vs. blank; * P<0.05, * * * P<0.001vs. diabetic groups;
The Spica Prunellae water extract of Fig. 6 different batches on the impact of diabetic mice BRB seepage (
n=6)
###p<0.001vs. blank; * * P<0.001vs. diabetic groups.
Detailed description of the invention
Appearance part of the present invention is based on so unexpected discovery: Chinese medicine Spica Prunellae water extract significantly can improve inflammatory damage and the BRB seepage of STZ inducing mouse diabetic retinopathy.Therefore, Spica Prunellae water extract can be expected to develop the medicine becoming a kind of prevention or treatment of diabetic retinopathy
And then a first aspect of the present invention there is provided the application of Spica Prunellae water extract in the medicine preparing prevention or treatment diabetic retinopathy or food, and described Spica Prunellae water extract is containing 0.1 ~ 20wt% rosmarinic acid.
Preferably, described Spica Prunellae water extract is containing 1.98wt% rosmarinic acid
Preferably, described diabetic retinopathy is non-proliferative diabetic retinopathy.
As known to persons skilled in the art, as the discriminating of Spica Prunellae in pharmacopeia and the index components of assay, rosmarinic acid (Rosmarinicacid) has following structural formula:
Spica Prunellae water extract of the present invention obtains from purchases such as Nanjing Zelang Pharmaceutical Technology Inc. by commercial sources, also extracts from Spica Prunellae by the conventional method of this area and obtains, such as: the post-heating that is soaked in water by Chinese medicine Spica Prunellae extracts concentrated obtained.
Spica Prunellae water extract of the present invention, can be used alone, or uses with the form of pharmaceutical composition.Pharmaceutical composition comprises Spica Prunellae water extract of the present invention as active component and pharmaceutically suitable carrier.Preferably, pharmaceutical composition of the present invention contains the Spica Prunellae water extract of the present invention as active component of 0.1-99.9% percentage by weight." pharmaceutically suitable carrier " can not destroy the pharmaceutical active of Spica Prunellae water extract of the present invention, simultaneously its effective dose, and consumption when can play pharmaceutical carrier effect is to human non-toxic.
Described pharmaceutically suitable carrier includes but not limited to: soft phospholipid, aluminium stearate, aluminium oxide, ion exchange material, self-emulsifying drug delivery system, tween or other surfactants, serum albumin, buffer substance are if phosphate, glycine, sorbic acid, water, salt, electrolyte are as sulfate protamine, sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, magnesium silicate, satisfied fatty acid partial glyceride mixtures etc.
Other conventional excipient substances are as binding agent (as microcrystalline Cellulose), filler (as starch, glucose, Lactis Anhydrous and lactose beadlet), disintegrating agent (as cross-linked pvp, crosslinked carboxymethyl fecula sodium, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose), lubricant (as magnesium stearate) and absorption enhancer, absorption carrier, flavouring agent, sweeting agent, excipient, diluent, wetting agent etc.
Spica Prunellae water extract of the present invention and its pharmaceutical composition can by the preparations of this area conventional method and can by intestinal or non-bowel or topical routes.Oral formulations comprises capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.; Non-intestinal drug delivery agent comprises injection etc.; Local administration preparation comprises cream, patch, ointment, spray etc.Be preferably oral formulations.
The route of administration of Spica Prunellae water extract of the present invention and its pharmaceutical composition can be oral, Sublingual, percutaneous, through muscle or subcutaneous, mucocutaneous, vein, urethra, vagina etc.
Except making medicament, also can add the various food additive such as antioxidant, pigment, enzyme preparation at Spica Prunellae water extract of the present invention, make health food by the conventional method of this area.
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, the usually conveniently conditioned disjunction condition of advising according to manufacturer.Unless otherwise indicated, otherwise all percent, ratio, ratio or number by weight.
Unless otherwise defined, all specialties used in literary composition and scientific words and one skilled in the art the same meaning be familiar with.In addition, any method similar or impartial to described content and material all can be applicable in the inventive method.The use that better implementation method described in literary composition and material only present a demonstration.
The above-mentioned feature that the present invention mentions, or the feature that embodiment is mentioned can combination in any.All features that patent specification discloses can with any composition forms and use, each feature disclosed in description, anyly can provide identical, alternative characteristics that is impartial or similar object replaces.Therefore apart from special instruction, the feature disclosed is only general example that is impartial or similar features.
The mensuration of rosmarinic acid (RA) content in embodiment 1 Spica Prunellae water extract
1.1 experiment materials and method
The preparation of Spica Prunellae water extract: each 100g of Spica Prunellae weighing different batches, beat powder or be cut to suitable drugs extract granule, fragment, add ten times of deionized waters and soak 1 hour, boiling water decocts 1.5 hours, collects decocting liquid, medical material decocts again, repeatedly extract three times altogether, collecting decoction, concentrating under reduced pressure evaporate to dryness, obtain the solid Spica Prunellae water extract of different batches, 4 DEG C of Refrigerator stores are for subsequent use.
The preparation of reference substance solution: get rosmarinic acid reference substance appropriate, accurately weighed, be placed in brown measuring bottle, add 50% methanol and make the reference substance solution of every 1ml containing 100 μ g, obtain (less than 10 DEG C preservations).
The preparation of need testing solution: precision takes Spica Prunellae water extract extractum in volumetric flask, adds 50% methanol, ultrasonic dissolution, crosses 0.22 μm of microporous filter membrane, obtains (less than 10 DEG C preservations).
Rosmarinic acid (RA) assay: chromatographic column is PhenomenexC18 post (4.6 × 250mm, 5 μm); Mobile phase condition is methanol-1% formic acid (40:60, v/v), and flow velocity is 1.0mL/min, isocratic elution; Sampling volume is 5 μ L; Column temperature is 25 DEG C; Determined wavelength is 330nm.
1.2 experimental result
The percentage composition of rosmarinic acid in table 1 different batches Spica Prunellae water extract
Embodiment 2: Spica Prunellae water extract (PV) improves drug activity and the mechanism thereof of diabetic retinopathy
2.1 experiment materials and method
2.1.1 animal: SPF level C57 mice, male, body weight 18-24g, purchased from Chinese Academy of Sciences's Shanghai Experimental Animal Center.The animal quality certification is numbered: SCXK (Shanghai) 2012-0002.Raise in Shanghai Univ. of Traditional Chinese Medicine SPF level Animal House, raise after one week and use.Rearing conditions is: temperature 22 ± 1 DEG C, humidity 55 ± 5%, and 12 hours Dark-light cycle, freely absorb after feedstuff and water sterilization.Test and carry out in strict accordance with country and Shanghai Univ. of Traditional Chinese Medicine's animal center animal use management regulations.
2.1.2 the preparation of medicine: get appropriate Spica Prunellae water extract (PV) extractum and be dissolved in normal saline, gastric infusion, concentration is 100mg/kg and 200mg/kg.
2.1.3 zoopery:
(1) 0.1M citric acid solution and citric acid three sodium solution are mixed with the ratio of 14:11, adjust mixed liquor PH to 4.3-4.5, stand-by.Take appropriate STZ powder, lucifuge is dissolved, and makes it the solution becoming 5.5mg/ml, and give the mouse peritoneal injection of fasting 12h immediately, 0.1ml/10g, the dosage finally giving STZ is 55mg/kg, successive administration 5 days.
(2) last administration one Zhou Houyong cuts tail method and surveys mouse blood sugar concentration, and blood glucose value >=16.7mmol/L (250mg/dl) is considered as modeling success.Successful for modeling mice is divided at random 3 groups: DR model group (DRmodel group), Spica Prunellae water extract 100mg/kg group, Spica Prunellae water extract 200mg/kg group, often organizes 16.16 of non-i.pSTZ normal C57 mices are as normal group (Control group) in addition.Within every two weeks, detect a body weight and change of blood sugar.
(3) modeling success started administration (0.1ml/10g) after 1 month, Spica Prunellae water extract 100mg/kg group, Spica Prunellae water extract 200mg/kg group gives the Spica Prunellae water extract solution of variable concentrations respectively, whole dosage is respectively: 100mg/kg, 200mg/kg, Model group gives the Vehicle controls of same volume, administration after 1 month often group get 6 mices and carry out Azo-Blue experiment, other remains 10 mice pentobarbital sodium (30mgkg-1, abdominal cavity) anesthesia, from abdominal aortic blood, and win eyeball, after rapid stripping retinal tissue, stored frozen is for subsequent use.
2.1.4 Azo-Blue seepage experiment: be dissolved in by Azo-Blue in PBS, compound concentration is 0.2gL
-1solution.Mouse peritoneal injection (10ulg
-1) the Azo-Blue solution prepared, after injection, 2h PBS pours into the Evans Blue dye that mice left ventricle thoroughly removes vasculature residence, then win rapidly eyeball to strip retinal tissue and put in centrifuge tube, weight is taken by after retinal tissue lyophilization, next retinal tissue and 120ul Methanamide are hatched 18h at 70 DEG C extracts Evans Blue dye, by centrifugal for this extracting solution twice (10000g, 4 DEG C), careful absorption merges supernatant, uses spectrophotometer to measure the absorbance of this supernatant at 620nm.The amount of Evans Blue dye in Methanamide extract calculates gained according to the standard curve made in advance, and result is expressed with the form of Azo-Blue content divided by dry retina weight.
2.1.5 enzyme immunoassay experiment: whole blood is after room temperature leaves standstill 2h, and in 4 DEG C, the centrifugal 15min of 4000g, is separated upper serum, detects the content of TNF-α and IL-1 β according to test kit description.
2.1.6 the extraction of endochylema karyon albumen: according to test kit operation instruction, the albumen of endochylema and karyon part in retinal tissue is extracted with endochylema/karyon Protein Extraction Reagent box, and use the protein concentration of BCA protein quantification kit measurement sample, by unified for all samples to equal protein concentration.
2.1.7 protein electrophoresis experiment: the albumen sample prepared carries out electrophoresis by SDS-PAGE glue, and albumen on glue is transferred to pvdf membrane, after closing 1h, adds primary antibodie, 4 DEG C of overnight incubation with the TBST solution containing 5% skim milk.After washing away primary antibodie, after washing away excessive antibodies with two anti-incubated at room 1h, TBST, add chemical luminescence for liquid and carry out video picture, protein band GeneTools image analysis software is carried out quantitatively.
2.1.8 statistical analysis: experimental data mean ± standard error (
) represent, adopt SPSS16.0 statistical software to analyze, carry out variance analysis in One-WayANOVA mode, compare between two and adopt LSD method, P<0.05 represents that difference has significance
2.2 experimental result
2.2.1 Spica Prunellae water extract (PV) is on the impact of blood glucose in diabetic mice and body weight
As seen from Figure 1, each dosage group of Spica Prunellae water extract all can not improve alleviating of diabetic mice body weight, can not reduce the blood glucose of rising.Illustrate that Spica Prunellae water extract does not have clear improvement the drug activity of diabetes.
2.2.2 Spica Prunellae water extract (PV) is on the impact of diabetic mice retina BRB seepage
As seen from Figure 2, STZ induction diabetic mice retina in Azo-Blue leakage values obviously raise (P<0.001), and PV (100,200mgkg
-1) all this is significantly improved to effect (P<0.001).The damage of blood retina barrier (BRB) is the feature of non-Proliferative diabetes retinopathy, our research shows: Spica Prunellae water extract can be alleviated BRB and damage the seepage caused, therefore have and improve diabetic retinopathy, particularly the drug activity of non-proliferative diabetic retinopathy.
2.2.3 Spica Prunellae water extract (PV) reduces IL-1 β, TNF-alpha content raised in diabetic mice serum
As shown in Figure 3, Interleukin-1β (IL-1 β) in the diabetic mice serum of STZ induction, tumor necrosis factor-alpha (TNF-α) content is apparently higher than normal group (P<0.05).With its contrast, PV (100,200mgkg
-1) in serum, the rising of IL-1 β, TNF-alpha content all obtains reduction (P<0.01, P<0.05, P<0.001) in various degree after administration.Our research shows: Spica Prunellae water extract, by suppressing the release of proinflammatory factor, is resisted retina inflammatory damage, improved diabetic retinopathy.
2.2.4 Spica Prunellae water extract (PV) Iba-1 in diabetic mice retina is expressed, the impact of NF-κ Bp65 phosphorylation and nuclear translocation
As visible in Fig. 4 A and 4B, in the diabetic mice retinal tissue of STZ induction, Iba-1 protein expression obviously raises (P<0.001).By comparison, PV (100,200mgkg
-1) significantly reduce the Iba-1 raised in retinal tissue after administration and express (P<0.001).Iba1 is the mark of neural Activated Microglia, has played important function in the process studies have found that the activation of neural microglia and the inflammatory damage of mediation thereof occur at diabetic retinopathy, developing.Our research shows: Spica Prunellae water extract by suppressing the activation of neural microglia, thus inhibits amphiblestroid inflammatory damage.
As shown in figures 5 a-c, compare with normal group, in STZ induced diabetes Mouse Retina tissue, the expression of phosphorylation NF-κ Bp65 albumen obviously increases (P<0.001), and in karyon, the expression of NF-κ Bp65 albumen also obviously increases (P<0.001).By comparison, PV (100,200mgkg
-1) expression (P<0.05 of the phosphorylation NF-κ Bp65 albumen of rising can be reduced after administration, P<0.001), also reduce the expression (P<0.001) of the NF-κ Bp65 albumen increased in karyon simultaneously, but on the expression of p65 albumen in endochylema without obvious impact.NF-κ B is the important inflammatory damage regulatory factor of body, and our research shows: Spica Prunellae water extract by suppressing NF-κ B signal path, thus inhibits amphiblestroid inflammatory damage in diabetic retinopathy process.
Embodiment 3: different batches Spica Prunellae water extract improves the drug activity of diabetic retinopathy
3.1 experiment materials and method
3.1.1 animal: SPF level C57 mice, male, body weight 18-24g, purchased from Chinese Academy of Sciences's Shanghai Experimental Animal Center.The animal quality certification is numbered: SCXK (Shanghai) 2012-0002.Raise in Shanghai Univ. of Traditional Chinese Medicine SPF level Animal House, raise after one week and use.Rearing conditions is: temperature 22 ± 1 DEG C, humidity 55 ± 5%, and 12 hours Dark-light cycle, freely absorb after feedstuff and water sterilization.Test and carry out in strict accordance with country and Shanghai Univ. of Traditional Chinese Medicine's animal center animal use management regulations.
3.1.2 the preparation of medicine: Spica Prunellae water extract (preparing by the embodiment 1) extractum getting appropriate different batches is dissolved in normal saline, and gastric infusion, concentration is 100mg/kg.
3.1.3 zoopery:
(1) 0.1M citric acid solution and citric acid three sodium solution are mixed with the ratio of 14:11, adjust mixed liquor PH to 4.3-4.5, stand-by.Take appropriate STZ powder, lucifuge is dissolved, and makes it the solution becoming 5.5mg/ml, and give the mouse peritoneal injection of fasting 12h immediately, 0.1ml/10g, the dosage finally giving STZ is 55mg/kg, successive administration 5 days.
(2) last administration one Zhou Houyong cuts tail method and surveys mouse blood sugar concentration, and blood glucose value >=16.7mmol/L (250mg/dl) is considered as modeling success.Successful for modeling mice is divided at random 5 groups: DR model group (DRmodel group), Spica Prunellae water extract (PV) group, Spica Prunellae water extract-1 (PV-1) group, Spica Prunellae water extract-2 (PV-2) group, Spica Prunellae water extract-3 (PV-3) group, often organizes 6.6 of non-i.pSTZ normal C57 mices are as normal group (Control group) in addition.
(3) modeling success started administration (0.1ml/10g) after 1 month, give the Spica Prunellae water extract solution of different batches respectively, dosage is: 100mg/kg, Model group gives the Vehicle controls of same volume, and the seepage that Azo-Blue experiment detects blood retina barrier (BRB) is carried out in administration after 1 month.
3.1.4 Azo-Blue seepage experiment: be dissolved in by Azo-Blue in PBS, compound concentration is 0.2gL
-1solution.Mouse peritoneal injection (10ulg
-1) the Azo-Blue solution prepared, after injection, 2h PBS pours into the Evans Blue dye that mice left ventricle thoroughly removes vasculature residence, then win rapidly eyeball to strip retinal tissue and put in centrifuge tube, weight is taken by after retinal tissue lyophilization, next retinal tissue and 120ul Methanamide are hatched 18h at 70 DEG C extracts Evans Blue dye, by centrifugal for this extracting solution twice (10000g, 4 DEG C), careful absorption merges supernatant, uses spectrophotometer to measure the absorbance of this supernatant at 620nm.The amount of Evans Blue dye in Methanamide extract calculates gained according to the standard curve made in advance, and result is expressed with the form of Azo-Blue content divided by dry retina weight.
3.2 experimental result
As seen from Figure 6, in the diabetic mice retina of STZ induction, Azo-Blue leakage values obviously raises (P<0.001), and PV (100mgkg
-1), PV-1 (100mgkg
-1), PV-2 (100mgkg
-1), PV-3 (100mgkg
-1) all this is significantly improved to effect (P<0.001).The damage of blood retina barrier (BRB) is the feature of non-Proliferative diabetes retinopathy, our research shows:: the Spica Prunellae water extract of each batch all can be alleviated BRB and damage the Azo-Blue seepage caused, therefore it has and improves diabetic retinopathy, the particularly drug activity of non-proliferative diabetic retinopathy.
Many aspects involved in the present invention have been done and have as above been set forth.It is to be understood, however, that put before not departing from spirit of the present invention, those skilled in the art can carry out equivalent change and modification to it, and described change and modification fall into the coverage of the application's claims equally.
Claims (3)
1. the application of Spica Prunellae water extract in the medicine preparing prevention or treatment diabetic retinopathy or food, described Spica Prunellae water extract is containing 0.1 ~ 20wt% rosmarinic acid.
2. the application of Spica Prunellae water extract as claimed in claim 1, wherein said Spica Prunellae water extract is containing 1.98wt% rosmarinic acid.
3. the purposes of Spica Prunellae water extract as claimed in claim 1, wherein said diabetic retinopathy is non-proliferative diabetic retinopathy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510604313.2A CN105106303B (en) | 2015-09-21 | 2015-09-21 | Medical application of selfheal aqueous extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510604313.2A CN105106303B (en) | 2015-09-21 | 2015-09-21 | Medical application of selfheal aqueous extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105106303A true CN105106303A (en) | 2015-12-02 |
| CN105106303B CN105106303B (en) | 2020-02-18 |
Family
ID=54654584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510604313.2A Active CN105106303B (en) | 2015-09-21 | 2015-09-21 | Medical application of selfheal aqueous extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106303B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112076250A (en) * | 2020-09-28 | 2020-12-15 | 南方医科大学 | Prunella vulgaris extract and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101332230A (en) * | 2008-01-23 | 2008-12-31 | 上海海天医药科技开发有限公司 | Prunella plant extract, preparation method and use thereof |
| CN101507751A (en) * | 2009-03-17 | 2009-08-19 | 江苏大学 | Use of Prunella vulgaris extract in preparing medicine for treating insomnia |
| CN102018759A (en) * | 2009-09-17 | 2011-04-20 | 上海中医药大学附属曙光医院 | Rosmarinic acid, rosmarinic acid-containing common selfheal fruit-spike active ingredient and preparation methods and application thereof to prevention and treatment of cancer postoperative metastasis |
| CN102670827A (en) * | 2012-05-11 | 2012-09-19 | 北京绿源求证科技发展有限责任公司 | Chinese medicine for treating diabetic retinopathy |
-
2015
- 2015-09-21 CN CN201510604313.2A patent/CN105106303B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101332230A (en) * | 2008-01-23 | 2008-12-31 | 上海海天医药科技开发有限公司 | Prunella plant extract, preparation method and use thereof |
| CN101507751A (en) * | 2009-03-17 | 2009-08-19 | 江苏大学 | Use of Prunella vulgaris extract in preparing medicine for treating insomnia |
| CN102018759A (en) * | 2009-09-17 | 2011-04-20 | 上海中医药大学附属曙光医院 | Rosmarinic acid, rosmarinic acid-containing common selfheal fruit-spike active ingredient and preparation methods and application thereof to prevention and treatment of cancer postoperative metastasis |
| CN102670827A (en) * | 2012-05-11 | 2012-09-19 | 北京绿源求证科技发展有限责任公司 | Chinese medicine for treating diabetic retinopathy |
Non-Patent Citations (2)
| Title |
|---|
| 张德志、丁淑华: "糖尿病性视网膜病变的中医药治疗概况", 《中国中医急症》 * |
| 黄幼霞、黄荣桂、郑兴中: "迷迭香酸药理作用的研究进展", 《海峡药学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112076250A (en) * | 2020-09-28 | 2020-12-15 | 南方医科大学 | Prunella vulgaris extract and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105106303B (en) | 2020-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102552462B (en) | Effervescent preparation as well as preparation method and application thereof | |
| CN104127761A (en) | Children's soft preparation for strengthening stomach and promoting digestion and preparation method thereof | |
| CN102846864B (en) | Chinese herbal veterinary medicine for preventing and treating swine infectious atrophic rhinitis and preparation process thereof | |
| CN101856418B (en) | Pharmaceutical preparation for preventing nephritis and preparation method thereof | |
| CN103585192B (en) | A kind of preparation method of Aleuritopteris argentea (Gmel.) Fee extract and application thereof | |
| CN104244937A (en) | Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin | |
| CN105106303A (en) | Medical application of selfheal aqueous extract | |
| CN106109564A (en) | Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof | |
| CN102641342B (en) | A kind of Chinese medicine extract and preparation method for the treatment of nephropathy | |
| CN109275811A (en) | It is a kind of with the composition of liver protection effect Rosa roxburghi Juice containing curcumin and its application | |
| CN106692289B (en) | Medical application of barbat skullcap alcohol extract | |
| CN103520515B (en) | Dendrobium chrysotoxum extract and medical usage thereof | |
| CN107184831B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| JP5265347B2 (en) | Use of konjac and its extract in formulating pharmaceuticals for the treatment of acute and chronic bronchitis | |
| CN104622967A (en) | Ficus carica containing pharmaceutical composition as well as preparation method and applications thereof | |
| CN104491359A (en) | Traditional Chinese medicine composition for treating oral ulcer and pharyngitis swelling and pain and preparation method thereof | |
| CN103877513A (en) | Chinese herbal compound composition with blood fat reduction effect, and applications thereof | |
| CN105012279A (en) | Composition containing kirenol and application thereof in medicament | |
| CN110448622B (en) | Medicine for treating heat type cold and preparation method and application thereof | |
| CN115381901B (en) | Pharmaceutical application of dendrobium liquid preparation | |
| CN115634276B (en) | Application of medicinal preparation for promoting diuresis and removing dampness in field of membranous nephropathy treatment | |
| CN1315506C (en) | Chinese medicine preparation for treating gynecologic inflammation | |
| CN105168398A (en) | Pharmaceutical composition for treating nephropathy and preparation method thereof | |
| CN104644768A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating kidney disease | |
| CN105327219A (en) | Traditional Chinese medicine composition for treating female pelvic inflammation and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |